Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 22239432)

1.

Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.

Meredith R, You Z, Alvarez R, Partridge E, Grizzle W, LoBuglio A.

Cancer Biother Radiopharm. 2012 Feb;27(1):36-40. doi: 10.1089/cbr.2011.1111. Epub 2012 Jan 12.

2.

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.

Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF.

Clin Cancer Res. 2002 Sep;8(9):2806-11.

3.

Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?

Grana C, Bartolomei M, Handkiewicz D, Rocca P, Bodei L, Colombo N, Chinol M, Mangioni C, Malavasi F, Paganelli G.

Gynecol Oncol. 2004 Jun;93(3):691-8.

PMID:
15196866
4.

Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.

Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ, Austin JM Jr, Kilgore LC, Grizzle WE, Schlom J, LoBuglio AF.

Cancer Biother Radiopharm. 2001 Aug;16(4):305-15.

PMID:
11603001
6.

Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.

Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF.

Clin Cancer Res. 2005 Nov 15;11(22):8180-5.

7.

Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.

Forero A, Meredith RF, Khazaeli MB, Shen S, Grizzle WE, Carey D, Busby E, LoBuglio AF, Robert F.

Cancer Biother Radiopharm. 2005 Oct;20(5):467-78.

PMID:
16248762
9.

Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.

Meredith RF, Partridge EE, Alvarez RD, Khazaeli MB, Plott G, Russell CD, Wheeler RH, Liu T, Grizzle WE, Schlom J, LoBuglio AF.

J Nucl Med. 1996 Sep;37(9):1491-6.

10.

Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.

Shen S, Forero A, Meredith RF, LoBuglio AF.

Cancer Biother Radiopharm. 2011 Feb;26(1):127-33. doi: 10.1089/cbr.2010.0864.

PMID:
21355784
11.

Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.

Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G, et al.

Clin Cancer Res. 1995 Dec;1(12):1447-54.

12.

Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclide.

Janssen ML, Pels W, Massuger LF, Oyen WJ, Boonstra H, Corstens FH, Boerman OC.

Int J Gynecol Cancer. 2003 Sep-Oct;13(5):607-13.

PMID:
14675343
13.

Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential.

Koi L, Bergmann R, Brüchner K, Pietzsch J, Pietzsch HJ, Krause M, Steinbach J, Zips D, Baumann M.

Radiother Oncol. 2014 Feb;110(2):362-9. doi: 10.1016/j.radonc.2013.12.001. Epub 2014 Jan 16.

PMID:
24440046
14.

Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.

Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.

Clin Cancer Res. 1999 May;5(5):953-61.

15.

Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.

Grünberg J, Lindenblatt D, Dorrer H, Cohrs S, Zhernosekov K, Köster U, Türler A, Fischer E, Schibli R.

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1907-15. doi: 10.1007/s00259-014-2798-3. Epub 2014 May 24.

PMID:
24859811
16.

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.

Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, Russell CD, Liu T, Grizzle WE, Schlom J, LoBuglio AF, Meredith RF.

Gynecol Oncol. 1997 Apr;65(1):94-101.

PMID:
9103398
17.

Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.

Greiner JW, Ullmann CD, Nieroda C, Qi CF, Eggensperger D, Shimada S, Steinberg SM, Schlom J.

Cancer Res. 1993 Feb 1;53(3):600-8.

18.

Human anti-mouse IgM and IgG responses in ovarian cancer patients after radioimmunotherapy with 90Y-muHMFG1.

Oei AL, Sweep FC, Geurts-Moespot A, van Tienoven D, Von Mensdorff-Pouilly S, Thomas CM, Massuger LF.

Anticancer Res. 2008 Sep-Oct;28(5A):2721-5.

20.

Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.

Crow DM, Williams L, Colcher D, Wong JY, Raubitschek A, Shively JE.

Bioconjug Chem. 2005 Sep-Oct;16(5):1117-25.

PMID:
16173788
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk